Special notice
FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
FDABAA-26-00123
Food and Drug Administration, FDA Office of Acquisitions and Grants Services. Research and Development in Biotechnology (except Nanobiotechnology).
Awarded
Institute for Clinical Pharmacodynamics, Inc.
$325,000.00 obligated so far on USAspending
Description
As published on SAM.gov.
Amendment 03 - Updated the announcement document to version 2.0. Changes are highlighted throughout the document.
Amendment 02 - Save the date! the FY26 Virtual BAA day - 20 January 2026! https://www.fda.gov/science-research/advancing-regulatory-science/2026-fda-broad-agency-announcement-day-01202026 Amendment 01 - Updated the announcement document to version 2.0. Changes are highlighted throughout the document.
In accordance with FAR 6.102(d)(2) and 35.016, the US Food and Drug Administration (FDA) solicits for the acquisition of basic and applied research and development proposals to support regulatory science and innovation through this Broad Agency Announcement (BAA).
Research and development activities acquired under this BAA are intended to advance scientific knowledge in specific research areas as well as sub areas of interest defined within the BAA that serve the FDA in accomplishing its mission to protect and promote the health of our nation. Proposals submitted under this announcement are not limited solely to the PSC code "AJ11" specified in this announcement. FDA funds extramural research through an agency-wide Broad Agency Announcement (BAA) for research and development to support regulatory science and innovation.
The contract, on USAspending
Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.
- UEI
- Z82HHPY83MC7
- CAGE
- 6Y2X5
- Vendor location
- Schenectady, NY
- Contract
- 75F40126C00025, definitive contract
- Obligated
- $325,000.00
- Actions
- 1 between June 30, 2026 and June 30, 2026
- Competition
- Competed Under SAP, 1 offer received
- Set-aside reported
- No Set Aside Used.
- Described as
- BAA Contract - Development of Susceptibility Guidance for Daptomycin and Enterococcus Species Using Pharmacometric Approaches
- Match
- solicitation number FDABAA2600123 equals the FPDS solicitation identifier; same sub-agency 7524 (high confidence)
- Record
- USAspending award page
- Recipient
- Certara UK Limited
- UEI
- WWBMG5E7KT69
- CAGE
- U03U4
- Vendor location
- Sheffield
- Contract
- 75F40126C00071, definitive contract
- Obligated
- $352,968.00, potential $1,083,957
- Actions
- 1 between September 9, 2026 and September 9, 2026
- Competition
- Full and Open Competition, 1 offer received
- Set-aside reported
- No Set Aside Used.
- Described as
- BAA Fy26c1cp53: Advancing Integration of in Vitro Topical Product Characterization and Skin Permeation Data
- Match
- solicitation number FDABAA2600123 equals the FPDS solicitation identifier; same sub-agency 7524 (high confidence)
- Record
- USAspending award page
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
November 21, 2025
Special notice
Due February 24, 2026 at 11:59 PM EST. SAM.gov, notice 803a5109fa3c49ebae21c22167a9a8d4
December 16, 2025
Special notice
Due February 24, 2026 at 5:00 PM EST. SAM.gov, notice 5f582391365645c2b030260aaf922e8b
January 6, 2026
Special notice
Due February 24, 2026 at 5:00 PM EST. SAM.gov, notice fc0fe580a8224192850fdb5f2ac40c4e
January 16, 2026
Special notice
Due February 24, 2026 at 5:00 PM EST. SAM.gov, notice 5622acb8db634d37b3b55d607e6ba561
Points of contact
- Ian WeissIan.Weiss@fda.hhs.gov3017965728